{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:44:17Z","timestamp":1790102657007,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T00:00:00Z","timestamp":1667088000000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["K01HL143034"],"award-info":[{"award-number":["K01HL143034"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P01CA87969"],"award-info":[{"award-number":["P01CA87969"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["R01CA163451"],"award-info":[{"award-number":["R01CA163451"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["U01CA176726"],"award-info":[{"award-number":["U01CA176726"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["UM1CA186107"],"award-info":[{"award-number":["UM1CA186107"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"NICHD","doi-asserted-by":"publisher","award":["K12HD085816"],"award-info":[{"award-number":["K12HD085816"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ygyno.2021.09.009","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:33:16Z","timestamp":1632184396000},"page":"342-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antihypertensive medication use and ovarian cancer survival"],"prefix":"10.1016","volume":"163","author":[{"given":"Tianyi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Dood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley S.","family":"Tworoger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.09.009_bb0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0010","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0015","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1470-2045(18)30373-5","article-title":"Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS\/NHSII): a cohort study","volume":"19","author":"Merritt","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0020","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm1447","article-title":"Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma","volume":"12","author":"Thaker","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0025","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1078-0432.CCR-05-1698","article-title":"Stress hormone-mediated invasion of ovarian cancer cells","volume":"12","author":"Sood","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0030","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/CLEP.S33695","article-title":"Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint","volume":"4","author":"Fitzgerald","year":"2012","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0040","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2019.05.030","article-title":"Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer","volume":"154","author":"Harding","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0045","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2012.07.102","article-title":"Impact of beta blockers on epithelial ovarian cancer survival","volume":"127","author":"Diaz","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0050","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1002\/cncr.29392","article-title":"Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer","volume":"121","author":"Watkins","year":"2015","journal-title":"Cancer."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0055","doi-asserted-by":"crossref","first-page":"101579","DOI":"10.1016\/j.canep.2019.101579","article-title":"Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study","volume":"62","author":"Couttenier","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-13-85","article-title":"Use of \u00df-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study","volume":"13","author":"Johannesdottir","year":"2013","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2021.09.009_bb0065","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ygyno.2020.03.012","article-title":"Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer","volume":"157","author":"Gonzalez","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0070","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.ygyno.2011.12.265","article-title":"Beta blocker use and ovarian cancer survival: a retrospective cohort study","volume":"125","author":"Eskander","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0075","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ygyno.2013.03.007","article-title":"Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG","volume":"129","author":"Heitz","year":"2013","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2016.11.012","article-title":"Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer","volume":"144","author":"Heitz","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0085","first-page":"13","article-title":"Antihypertensive drug use and the risk of ovarian cancer death among Finnish ovarian cancer patients-a nationwide cohort study","author":"Santala","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2021.09.009_bb0090","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1161\/CIRCULATIONAHA.112.096156","article-title":"Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010","volume":"126","author":"Gu","year":"2012","journal-title":"Circulation."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0095","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/aje\/kwj128","article-title":"Intake of folate and related nutrients in relation to risk of epithelial ovarian cancer","volume":"163","author":"Tworoger","year":"2006","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ijc.30066","article-title":"Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer","volume":"139","author":"Huang","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.09.009_bb0105","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00001648-199011000-00009","article-title":"Validity of self-reported waist and hip circumferences in men and women","volume":"1","author":"Rimm","year":"1990","journal-title":"Epidemiology."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1757-2215-7-41","article-title":"Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysis","volume":"7","author":"Bae","year":"2014","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0115","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/bjc.2015.245","article-title":"Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium","volume":"113","author":"Nagle","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.09.009_bb0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-319-42542-9_9","article-title":"Obesity and ovarian cancer","volume":"208","author":"Tworoger","year":"2016","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0125","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/ijc.32773","article-title":"Prediagnosis and postdiagnosis smoking and survival following diagnosis with ovarian cancer","volume":"147","author":"Wang","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.09.009_bb0130","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0735-1097(99)00447-7","article-title":"Calcium channel blockers, apoptosis and cancer: is there a biologic relationship?","volume":"34","author":"Mason","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0135","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/07357907.2011.568565","article-title":"Blockade of T-type Ca(2+) channels inhibits human ovarian cancer cell proliferation","volume":"29","author":"Li","year":"2011","journal-title":"Cancer Investig."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0140","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1016\/j.bmcl.2013.10.049","article-title":"In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers","volume":"23","author":"Jang","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0145","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.canep.2013.09.001","article-title":"Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study","volume":"37","author":"Holmes","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0150","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jamainternmed.2013.9071","article-title":"Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years","volume":"173","author":"Li","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0155","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6","article-title":"Use of calcium channel blockers and breast carcinoma risk in postmenopausal women","volume":"80","author":"Fitzpatrick","year":"1997","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.ygyno.2021.09.009_bb0160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/EDE.0000000000000814","article-title":"Post-diagnostic calcium channel blocker use and breast cancer mortality: a population-based cohort study","volume":"29","author":"Busby","year":"2018","journal-title":"Epidemiology."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0165","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1055-9965.EPI-17-0096","article-title":"Use of calcium channel blockers and breast cancer risk in the women\u2019s health initiative","volume":"26","author":"Brasky","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0170","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1001\/jamainternmed.2014.3867","article-title":"Breast cancer risk and use of calcium channel blockers using Swedish population registries","volume":"174","author":"Bergman","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0175","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1158\/1055-9965.EPI-17-0346","article-title":"Use of antihypertensive medications and risk of adverse breast cancer outcomes in a SEER-medicare population","volume":"26","author":"Chen","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0180","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2021.09.009_bb0185","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/1078-0432.CCR-04-1946","article-title":"Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination","volume":"11","author":"Suganuma","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0190","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/JCP.0b013e31820482c4","article-title":"\u03b2-blockers and the risk of incident depression in the elderly","volume":"31","author":"Luijendijk","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0195","first-page":"447","article-title":"Beta-blockers and depression in elderly hypertension patients in primary care","volume":"46","author":"Ringoir","year":"2014","journal-title":"Fam. Med."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0200","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2015.10.004","article-title":"Depression and risk of epithelial ovarian cancer: results from two large prospective cohort studies","volume":"139","author":"Huang","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0205","first-page":"661","article-title":"A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients","volume":"27","author":"Poole","year":"2016","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ygyno.2021.09.009_bb0210","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1017\/S0033291709992285","article-title":"Depression and cancer mortality: a meta-analysis","volume":"40","author":"Pinquart","year":"2010","journal-title":"Psychol. Med."},{"key":"10.1016\/j.ygyno.2021.09.009_bb0215","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1158\/1055-9965.EPI-16-0534","article-title":"Association of ovarian tumor \u03b22-adrenergic receptor status with ovarian cancer risk factors and survival","volume":"25","author":"Huang","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:57:44Z","timestamp":1758772664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821013780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0090825821013780"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.09.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antihypertensive medication use and ovarian cancer survival","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}